
|Videos|November 9, 2021
A Deep Dive on Tapinarof
Author(s)Mary Scoviak, Managing Editor
In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.
Advertisement
Mark G. Lebwohl, MD, professor of dermatology at Mount Sinai, New York, New York, details how tapinarof cream (GSK2894512; Dermavant), a once-daily topical aryl hydrocarbon receptor (AhR) agonist, is effective for psoriasis, gives his thoughts on the current treatment pipeline, and more in this video interview.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











